Rheumatoid in Medical News

TNF Blockers May Help Some With Rheumatoid Arthritis

If standard treatment fails, more intensive therapy works well, study finds THURSDAY, Aug. 6 (HealthDay News) -- Patients with early rheumatoid arthritis (RA) who respond poorly to standard treatment with methotrexate may benefit from additional treatment with tumor necrosis factor (TN...

Decision Resources' Updated Rheumatoid Arthritis Report Now Includes Forecast for Rigel Pharmaceuticals' Fostamatinib Disodium

WALTHAM, Mass., Aug. 6 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, today released its updated Pharmacor Rheumatoid Arthritis report which now includes patient share and sales forecasts through 2018...

Lexicon Initiates Phase 2 Clinical Trial of LX2931 in Patients With Rheumatoid Arthritis

THE WOODLANDS, Texas, Aug. 4 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has initiated a Phase 2 cli...

Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi3 Clinical Trial of R788 in Rheumatoid Arthritis

SOUTH SAN FRANCISCO, Calif., July 23 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced that the Company plans to host a conference call on Thursday, July 23, 2009 at 7:00 pm EDT (4:00 pm PDT). Members of Rigel's senior management team and the p...

For Treatment of Rheumatoid Arthritis, Surveyed Rheumatologists and Patients Differ In Their Perception of Bristol-Myers Squibb's Orencia

WALTHAM, Mass., July 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that surveyed rheumatologists' perception of Bristol-Myers Squibb's Orencia is low among rheumatoid arthrit...

Brazil's Rheumatoid Arthritis Drug Market Will Grow $115 Million by 2013

WALTHAM, Mass., July 20 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the rheumatoid arthritis drug market in Brazil will grow from $200 million in 2008 to more than $315 m...

China's Rheumatoid Arthritis Drug Market Will More than Double by 2013

WALTHAM, Mass., July 13 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the rheumatoid arthritis (RA) drug market will more than double by 2013, growing from $138 million in 2008 to $3...

New Drug Promising Against Rheumatoid Arthritis

Golimumab might help where similar drugs failed, research finds MONDAY, June 29 (HealthDay News) -- The immunosuppressive drug golimumab shows promise in treating rheumatoid arthritis patients who don't respond to other drugs, according to a new study. Golimumab is from the family of d...

Over half of people with rheumatoid arthritis have periodontitis

Copenhagen, Denmark, Friday 12 June 2009: Over half (56%) of people with rheumatoid arthritis (RA) also have periodontitis (a chronic inflammatory disease of the gum and surrounding ligaments and bones that hold the teeth in place), displaying fewer teeth than healthy matched controls, high preval...

Exercise improves functional and psycological ability and reduces steroid need in rheumatoid arthritis

Copenhagen, Denmark, Thursday 11 June 2009: Undertaking a supervised exercise programme can have beneficial effects on functional status and physical function, reduce the need for daily corticosteroid and anti-inflammatory intake and improve levels of depression and anxiety in people with rheumato...

Treating gum disease helps rheumatoid arthritis sufferers

CLEVELAND Here's one more reason to keep your teeth healthy. People, who suffer from gum disease and also have a severe form of rheumatoid arthritis, reduced their arthritic pain, number of swollen joints and the degree of morning stiffness when they cured their dental problems. Researchers f...

For the Treatment of Rheumatoid Arthritis, Market Share for TNF-alpha Inhibitors Will Decrease Through 2018

Actemra/RoActemra Will Emerge as the Preferred Biological Drug for TNF-Refractory Patients, According to a New Report from Decision Resources WALTHAM, Mass., May 18 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare iss...

Nektar Announces UCB's Cimzia(R) Approved by U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis

Nektar Advanced Polymer Conjugate Technology Used in Cimzia(R) Through Exclusive Nektar-UCB Collaboration SAN FRANCISCO, Calif., May 14 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR ) confirmed today UCB's announcement that the US Food and Drug Administration (FDA) has approve...

UCB's CIMZIA(R) (certolizumab pegol) Approved by the U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis

- Available this week, Cimzia(R) (certolizumab pegol), the only pegylated anti-TNF, offers a new treatment option for U.S. adult patients suffering from moderately to severely active rheumatoid arthritis - Patients treated with Cimzia(R), together with methotrexate, experienced rapid and sign...

SIMPONI(TM) (golimumab) Receives FDA Approval as First Once-Monthly Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

First Subcutaneous Anti-TNF to Launch with Three Rheumatic Indications Simultaneously and with Novel SmartJect(TM) Autoinjector HORSHAM, Pa., April 24 /PRNewswire/ -- Centocor Ortho Biotech Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI (golimumab)...

Medarex to Receive Milestone Payment for Approval of SIMPONI(TM) for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

- The second approved antibody generated from Medarex's UltiMAb(R) technology platform - PRINCETON, N.J., April 14 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX ) today announced that it will receive a milestone payment of an undisclosed amount from its licensing partner, Centocor O...

Genetic risk factors play role in autoantibody-negative rheumatoid arthritis

During the past few years, several new genetic risk factors for rheumatoid arthritis (RA) have been identified. The majority of genetic risk factors identified so far have been associated with autoantibody-positive RA, which affects about two-thirds of RA patients, but distinguishing this variant ...

Patient preferences play role in racial disparities in rheumatoid arthritis treatment

Racial disparities in the delivery of healthcare occur even among insured populations with access to care. This suggests that some of the differences in health care utilization among different racial groups may be due to patient preferences. Rheumatoid arthritis (RA) treatment decisions are freque...

Living Near Major Road May Boost Rheumatoid Arthritis Risk

And women closest to traffic were 63 percent more likely to develop the disease, study says WEDNESDAY, April 1 (HealthDay News) -- People exposed to high levels of traffic pollution have an increased risk of rheumatoid arthritis, a new study suggests. Researchers analyzed the recor...

Frost & Sullivan: Rheumatoid Arthritis Therapeutics in Malaysia

KUALA LUMPUR, Malaysia, March 31 /PRNewswire/ -- Rheumatoid arthritis (RA) is a systemic disease or an autoimmune disorder in which the body's defense system attacks the joints through the thin layer of cells called the synovium that lines and lubricates the joints. The most visible symptoms of RA...

BioTrends Prepares to Field ChartTrends(TM) Reports to Cover the Use of Biologic Agents in Psoriasis and Rheumatoid Arthritis

EXTON, Pa., March 16 /PRNewswire/ -- BioTrends Research Group, Inc. has been covering the biologics market for Psoriasis and RA through its TreatmentTrends(TM) series which are syndicated primary research reports based on self reported survey data collected from Dermatologists and Rheumatologi...

Immune cells from patients with rheumatoid arthritis have prematurely aged chromosomes

Telomeres, structures that cap the ends of cells' chromosomes, grow shorter with each round of cell division unless a specialized enzyme replenishes them. Maintaining telomeres is thought to be important for healthy aging and cancer prevention. By this measure, T cells, or white blood cells, fr...

Gene Therapy May Ease Rheumatoid Arthritis

2 women who got injections report reduced pain and swelling FRIDAY, Feb. 6 (HealthDay News) -- The first evidence that gene therapy can ease symptoms in people with rheumatoid arthritis (RA) has been reported by American and German researchers. The study included two postmenopausa...

Process found to play role in rheumatoid arthritis could lead to new treatment

Although the origin of rheumatoid arthritis (RA) remains unclear, bioactive proteins known as cytokines, particularly TNFα and IL-6, which are involved in inflammation, play a major role in the disease by contributing to joint and tissue destruction. Placenta growth factor (PIGF), another cyt...

Current and Emerging Therapies Have No Advantage Over Enbrel in Reducing the Signs and Symptoms of Rheumatoid Arthritis

Golimumab Will Earn Decision Resources' Gold Standard for Rheumatoid Arthritis in 2012, According to a New Report from Decision Resources WALTHAM, Mass., Jan. 28 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues...

Growth Opportunities for Actemra Will Propel Roche to Sixth Position in the Rheumatoid Arthritis Market by 2012

Recent Entrants Invest Heavily in Promotion to Capture Share in Mature Market, According to a New Report from Decision Resources WALTHAM, Mass., Jan. 14 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues,...

CEL-SCI Launches Study to Determine Long Lasting Beneficial Effects of its Rheumatoid Arthritis Vaccine

Results expected to Support Licensing Activities VIENNA, Va., Jan. 7 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Alternext US : CVM ) announced today the initiation of a definitive study of its new rheumatoid arthritis treatment vaccine (CEL-2000) to determine the long-lasting b...

Medicaid policies vary widely for rheumatoid arthritis drugs

Patients with inflammatory diseases such as rheumatoid arthritis now have many more treatment options than in the past, including biologic disease-modifying antirheumatic drugs (DMARDs). These drugs, derived by modifying substances found in humans or animals, slow progression of the disease rather...

Wide variability in rheumatoid arthritis drug suggests alternative dosing should be considered

Methotrexate (MTX) is commonly used to treat rheumatoid arthritis (RA) and is suggested as the "anchor" drug in treating the disease. Despite its widespread use, the understanding of its mechanism of action and pharmacokinetics is limited. Since joint damage occurs early in the course of RA and is...

Biologics Don't Raise Cancer Risk in Rheumatoid Arthritis Patients

Review finds no connection between drugs that block tumor necrosis factor and malignancies TUESDAY, Oct. 28 (HealthDay News) -- TNF-antagonists, drugs widely used to treat rheumatoid arthritis (RA), don't appear to cause cancer, say Spanish researchers who analyzed data on more than 4...

New Study Highlights Need for Better Interaction and Education Between Rheumatoid Arthritis Patients and Care Providers

Study Also Underscores High Level of Patient Dissatisfaction with Pain Management SAN FRANCISCO, Oct. 28 /PRNewswire/ -- 5:00 am PDT -- UCB announced today findings from large-scale rheumatoid arthritis (RA) surveys collectively called the DESIGN study that showed patients rating themselves ...

Enbrel(R) (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Continuous Use for the Treatment of Moderate to Severe Rheumatoid Arthritis

SAN FRANCISCO, Oct. 27 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN ) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE ), today announced that ENBREL is the first biologic with published clinical trial data to show sustained improvements in multiple measures of efficacy in moderate...

Eighty-Nine Percent of Surveyed Rheumatologists Say They Will Prescribe Roche/Chugai's Actemra for Rheumatoid Arthritis

However, Pharmacy Directors Disagree About Formulary Inclusion for Key Emerging Biologic Agents That Will Launch for the Disease in the Next Few Years, According to a New Report from Decision Resources WALTHAM, Mass., Aug. 6 /PRNewswire/ -- Decision Resources, one of the world's leadi...

New Survey Findings Reveal Emotional and Physical Toll of Rheumatoid Arthritis and the Advancement of Treatment Through 'Generations'

Survey Results Capture Perspectives of People Living with Rheumatoid Arthritis and Physicians Treating the Condition over a Span of 30 Years HORSHAM, Pa., July 15 /PRNewswire/ -- Emotional and physical limitations are significant challenges cited by people diagnosed with rheumatoid arthrit...

FDA Advisory Committee Recommends Approval of ACTEMRA(R) (tocilizumab) for the Treatment of Rheumatoid Arthritis

- First interleukin-6 (IL-6) inhibitor to offer new therapeutic option for rheumatoid arthritis - NUTLEY, N.J., July 29 /PRNewswire/ -- Roche today announced that the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) by a near unanimous (10-1) v...

New Survey Findings Reveal Emotional and Physical Toll of Rheumatoid Arthritis and the Advancement of Treatment through "Generations"

Survey Results Capture Perspectives of People Living with Rheumatoid Arthritis and Physicians Treating the Condition over a Span of 30 Years Horsham, PA (Vocus) July 15, 2008 -- Emotional and physical limitations are significant challenges cited by people diagnosed wi...

High Birth Weight Doubles Risk of Rheumatoid Arthritis

Hormonal effects may be to blame, researchers say MONDAY, June 30 (HealthDay News) -- The risk of rheumatoid arthritis is twice as high in women who had a heavy birth weight (more than 10 pounds) than those with an average birth weight (7 to 8.5 lbs), a new study finds. Researchers ...

Heavy birthweight increases risk of developing rheumatoid arthritis

New York, June 30, 2008 People who have a birthweight over 10 pounds are twice as likely to develop rheumatoid arthritis when they are adults compared to individuals born with an average birthweight, according to a study published by researchers from Hospital for Special Surgery online in advance ...

Heavy birthweight babies twice as likely to develop rheumatoid arthritis

Heavy birthweight female babies are twice as likely to develop rheumatoid arthritis in adulthood as their average birthweight peers, suggests research published ahead of print in the Annals of the Rheumatic Diseases . The results support the fetal origin of disease theory, which argues that cer...

Centocor, Inc. Submits Application to FDA Requesting Approval of Golimumab for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Extensive Clinical Development Program Investigating Golimumab in the Treatment of These Diseases Serves as Basis for the Application HORSHAM, Pa., June 27 /PRNewswire/ -- Centocor, Inc. announced today that a Biologics License Application (BLA) has been submitted to the U.S. Food and Drug...